Cases from the Community: Clinical Investigators Provide Their Perspectives on Actual Breast Cancer Cases and the Implications of Emerging Research — A Special Audio Supplement


Interview with Kimberly L Blackwell, MD

Track 1: Duration of pertuzumab/trastuzumab maintenance for metastatic HER2-positive disease
Track 2: Locoregional therapy in patients with metastatic disease
Track 3: Management of diarrhea in patients receiving pertuzumab
Track 4: Management of oligometastatic disease to the bone
Track 5: Case: A 33-year-old woman with ER/PR-positive infiltrating ductal carcinoma (IDC), 2 positive nodes and a 21-gene assay Recurrence Score® (RS) of 7
Track 6: Utility of the 21-, 70-gene and PAM50 assays in clinical practice
Track 7: Case: A 35-year-old woman with an 8.5-cm, Grade I, ER/PR-positive, HER2-negative, node-positive IDC and an RS of 15
Track 8: Case: A 41-year-old woman previously treated for HER2-positive disease presents with locally advanced triple-negative breast cancer (TNBC) in the ipsilateral breast
Track 9: Case: A 35-year-old woman with TNBC and local disease recurrence
Track 10: Therapeutic approach for younger patients with BC and a germline BRCA mutation

Interview with Joyce O’Shaughnessy, MD

Track 1: Case: A 51-year-old woman with ER-positive, HER2-negative lobular BC treated with 5 years of tamoxifen presents 1 year later with a local recurrence
Track 2: Case: A 33-year-old pregnant woman with ER/PR-positive, HER2-positive locally advanced BC
Track 3: Update of a combined analysis of the TEXT and SOFT trials: Adjuvant exemestane with ovarian function suppression (OFS) versus tamoxifen and OFS for premenopausal women with HR-positive early BC
Track 4: Factors influencing use and duration of adjuvant pertuzumab
Track 5: Risks of anti-HER2 therapy for pregnant patients
Track 6: Clinical utility of postadjuvant neratinib
Track 7: Case: A 42-year-old woman with a 1.8-cm, Grade III, ER/PR-negative, HER2-positive, node-negative BC
Track 8: Case: A 50-year-old postmenopausal woman with a 1.3-cm, Grade II, strongly ER/PR-positive, “HER2-positive” invasive lobular carcinoma
Track 9: Case: A 40-year-old woman with a 3.7-cm, Grade II, ER/PR-positive, HER2-negative suspected ductal carcinoma with 1 of 17 positive nodes declines adjuvant chemotherapy
Track 10: Evolution of circulating tumor DNA analyses as a diagnostic tool
Track 11: Case: A 45-year-old woman with triple-negative IDC and 2 large palpable lymph nodes achieves a pathologic complete response to neoadjuvant AC→T
Track 12: Perspective on the potential addition of carboplatin to neoadjuvant chemotherapy for TNBC
Track 13: Therapeutic options for patients with ER-positive, HER2-negative, BRCA2 germline mutation-positive BC and residual disease after neoadjuvant chemotherapy and surgery
Track 14: Reliability and concordance of Ki-67 testing
Track 15: Viewpoint on the clinical utility of the 21- and 70-gene assays for patients with 1 to 3 positive lymph nodes
Kimberly L Blackwell, MD
Professor of Medicine
Director, Breast Cancer Program
Duke Cancer Institute
Durham, North Carolina
Joyce O’Shaughnessy, MD
Breast Cancer Research Program
Baylor Charles
A Sammons Cancer Center
Celebrating Women
Chair in Breast Cancer Research
Texas Oncology
US Oncology
Dallas, Texas
Neil Love, MD
Research To Practice
Miami, Florida